Engineering a novel, stable dimeric streptavidin with lower isoelectric point

被引:14
作者
Aslan, Filiz M.
Yu, Yong
Vajda, Sandor
Mohr, Scott C.
Cantor, Charles R.
机构
[1] Boston Univ, Ctr Adv Biotechnol, Boston, MA 02215 USA
[2] Boston Univ, Dept Chem, Boston, MA 02215 USA
[3] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA
[4] Boston Univ, Biomol Engn Res Ctr, Boston, MA 02215 USA
[5] Sequenom Inc, San Diego, CA 92121 USA
关键词
biotin binding; dimeric streptavidin; molecular modeling; protein engineering; protein-protein interaction; radioimmunotherapy;
D O I
10.1016/j.jbiotec.2006.08.014
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];
摘要
We have engineered a soluble, stable two-chain dimeric streptavidin (TCD) in Escherchia coli. Examination of the three-dimensional structure of streptavidin aided by empirical binding free-energy calculations helped us to select mutations at subunit interfaces that dissociate the native tetramer and stabilize the desired dimer. We chose positions W120, L124, V125 and H127 and mutated them to 120D/124D/125D/127D (TCD-1); 120D/124N/125S/127D (TCD-2); and 120D/124D/125S/127D(TCD-3). The H127D mutation creates electrostatic repulsion that disrupts the dimer-dimer interface, but leaves it very hydrophobic. Therefore, W120, L124 and V125 were mutated to hydrophilic residues to increase dimer solubility. Among the three candidates, TCD-2 gave the best result: a stable, active dimer with K-d for biotin of similar to 1 x 10(-7) M after purification by gel-filtration chromatography. The experimental results confirm the possibility of rational engineering of low-pI dimeric streptavidins. Reduced-size streptavidin mutants with a net negative charge may be more suitable than antibodies or wild-type streptavidin for the targeting step in radioimmunotherapy because they should clear faster from the bloodstream and the kidney. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:213 / 225
页数:13
相关论文
共 32 条
[1]
Engineered single-chain dimeric streptavidins with an unexpected strong preference for biotin-4-fluorescein [J].
Aslan, FM ;
Yu, Y ;
Mohr, SC ;
Cantor, CR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (24) :8507-8512
[2]
ASLAN FM, 2005, THESIS BOSTON U BOST
[3]
Boerman OC, 2003, J NUCL MED, V44, P400
[4]
CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217
[5]
SITE-DIRECTED MUTAGENESIS STUDIES OF THE HIGH-AFFINITY STREPTAVIDIN-BIOTIN COMPLEX - CONTRIBUTIONS OF TRYPTOPHAN RESIDUE-79, RESIDUE-108, AND RESIDUE-120 [J].
CHILKOTI, A ;
TAN, PH ;
STAYTON, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1754-1758
[6]
Chu V, 1998, PROTEIN SCI, V7, P848
[7]
Protein biochemistry - Streptavidin surprises [J].
Doerr, A .
NATURE METHODS, 2005, 2 (08) :573-573
[8]
SOLVATION ENERGY IN PROTEIN FOLDING AND BINDING [J].
EISENBERG, D ;
MCLACHLAN, AD .
NATURE, 1986, 319 (6050) :199-203
[9]
Structural studies of binding site tryptophan mutants in the high-affinity streptavidin-biotin complex [J].
Freitag, S ;
Le Trong, I ;
Chilkoti, A ;
Klumb, LA ;
Stayton, PS ;
Stenkamp, RE .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 279 (01) :211-221
[10]
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy [J].
Goldenberg, DM ;
Sharkey, RM ;
Paganelli, G ;
Barbet, J ;
Chatal, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (05) :823-834